...
首页> 外文期刊>Hepatology research: the official journal of the Japan Society of Hepatology >Comparison of surgical outcomes in patients with colorectal liver metastases versus non-colorectal liver metastases: A Chinese experience
【24h】

Comparison of surgical outcomes in patients with colorectal liver metastases versus non-colorectal liver metastases: A Chinese experience

机译:大肠肝转移与非大肠肝转移患者手术结局的比较:中国经验

获取原文
获取原文并翻译 | 示例

摘要

Aim: To compare the surgical treatment outcomes between patients with colorectal liver metastases (CLM) and non-colorectal liver metastases (NCLM). Methods: The study population consisted of 132 patients undergoing hepatectomy at Tianjin Medical University Cancer Hospital between January 1996 and December 2008. Survival analyses were used to assess the differences in prognosis and survival between groups. Results: The primary tumor site was colorectal in 60 (45.5%), breast in 16 (12.1%), lung in 14 (10.6%), non-colorectal gastrointestinal in 12 (9.1%), genitourinary in 10 (7.6%), pancreatobiliary tumor (n=8, 6.1%) and others in 12 (9.1%). A curative liver resection was performed in all patients by pathological findings. After a median follow-up of 32months, the overall 3- and 5-year survival rate was 44.7 and 29.5% in all patients, respectively. The 3- and 5-year survival rates were 53.3 and 36.7% for liver metastases from colorectal tumors, 62.5 and 43.8% from breast, 60.0 and 40.0% from genitourinary neoplasm, 41.7 and 25.0% from non-colorectal gastrointestinal cancer, 28.5 and 15.0% from lung, 12.5 and 0% from pancreatobiliary malignancies, and 41.7 and 8.3% from other sites, respectively. Conclusions: Hepatic resection is an effective and safe treatment for liver metastases mainly depending on primary tumor sites. Hepatic metastases from non-colorectal gastrointestinal cancer, pulmonary and pancreatobiliary malignancies have the worst prognosis; those from breast and genitourinary neoplasm show the best prognosis.
机译:目的:比较大肠肝转移(CLM)和非大肠肝转移(NCLM)患者的手术治疗效果。方法:研究人群包括1996年1月至2008年12月在天津医科大学肿瘤医院接受肝切除术的132例患者。采用生存分析评估两组之间的预后和生存差异。结果:原发肿瘤部位为大肠直肠癌60例(45.5%),乳腺16例(12.1%),肺部14例(10.6%),非结肠直肠胃肠道12例(9.1%),泌尿生殖系统10例(7.6%),胰胆管肿瘤(n = 8,6.1%),其他12个(9.1%)。通过病理检查对所有患者进行治愈性肝切除。中位随访32个月后,所有患者的3年和5年总生存率分别为44.7和29.5%。大肠肿瘤肝转移的3年和5年生存率分别为53.3和36.7%,乳腺癌为62.5和43.8%,泌尿生殖道肿瘤为60.0和40.0%,非大肠胃癌为41.7和25.0%,28.5和15.0分别来自肺脏的百分比,胰腺胆道恶性肿瘤的12.5%和0%,以及其他部位的41.7和8.3%。结论:肝切除术是一种有效且安全的肝转移治疗方法,主要取决于原发肿瘤部位。非结直肠胃肠道癌的肝转移,肺和胰胆管恶性肿瘤的预后最差;乳腺和泌尿生殖系统肿瘤的预后最好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号